Clinical trial NCT04320342: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
Official title: A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: COPD
COPD Exacerbation
Keywords: Lung Function
Safety Profile
Beclomethasone Dipropionate
Glycopyrronium Bromide
Formoterol Fumarate
Lead sponsor: Chiesi Farmaceutici S.p.A.
Sponsor class: INDUSTRY
First posted: 2020-03-25
Enrollment: 3433
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.

Detailed description: This is a phase III, multinational, multicenter, randomized, double-blind active controlled 2-arm parallel group study to compare efficacy, safety, and tolerability of CHF 5993 pMDI with CHF 1535 pMDI with respect to lung function, incidence of moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes.

After screening, eligible subjects will enter 2-week run-in period using their regular COPD maintenance therapies after which they will be randomized to one of 2 study treatment groups. Following randomization, subjects will be assessed after 4 weeks then at 6-week intervals thereafter for a period of 52 weeks. A follow-up safety phone call will be performed a week after the last clinic visit. A subset of subjects consenting to participate in the pharmacokinetic substudy will undergo additional assessments (totaling 3 visits) during the scheduled study visits.

During the study, daily symptoms, rescue medication use and compliance with the study drug will be recorded via a subject electronic diary. Subject concomitant medications, adverse events, and healthcare resource utilization will be assessed and recorded throughout the study. At intermittent study visits, subjects will undergo vital signs examinations including weight, spirometry measurements, and 12-lead ECG. Symptoms and COPD health status will be assessed through disease specific questionnaires. Routine hematology, blood chemistry, and serum pregnancy testing will be performed before enrollment and at end of study.

Eligibility criteria: Inclusion Criteria:

* Signed and dated written informed consent must be obtained prior to initiating any study-related procedures
* Outpatient
* Male or female subjects aged ≥40 years
* Female subjects:

  1. WOCBP fulfilling one of the following criteria: i. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method from the signing of the informed consent form and until the follow-up contact or ii. WOCBP with non-fertile male partners (contraception is not required in this case).
  2. Female subjects of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. post-menopausal or permanently sterile as per definitions given in Appendix 5). Tubal ligation or partial surgical interventions are not acceptable. If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges)
* COPD diagnosis for at least 12 months before the screening visit in accordance with the definition by the GOLD 2020 Report
* Current or ex-smokers who quit smoking at least 6 months prior to screening with a smoking history of at least 10 pack-years \[pack-years = (number of cigarettes per day x number of years)/20\]
* COPD Assessment Test (CAT) score ≥10
* A pre- and post-bronchodilator FEV1/FVC ratio \<0.70 at screening
* A post-bronchodilator FEV1 \<50% predicted normal at screening and a documented history of ≥1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator FEV1 ≥50% and \<80% of predicted normal at screening and a documented history of ≥2 moderate COPD exacerbations or ≥1 severe COPD exacerbation in the previous 12 months
* Subjects receiving daily inhaled maintenance therapy for their COPD, at a stable dose for at least 3 months prior to the screening and randomization visits
* Documentation (including imagery and report) of chest x-ray (CXR) or CT scan performed within 6 months prior to the screening visit, without evidence of significant abnormalities (other than those related to the presence of COPD).
* A cooperative attitude and ability to demonstrate correct use of the pMDI inhalers and eDiary.

Exclusion Criteria:

* Female subjects who are pregnant (as evident by a positive urine hCG or serum β-hCG test) or lactating
* Subjects using the following medications prior to the screening visit and during the run-in period:

  1. Systemic/oral/parenteral corticosteroids in the prior 4 weeks
  2. Use of antibiotics for a lower respiratory tract infection (e.g. pneumonia) or COPD exacerbation in the prior 4 weeks
  3. Any long-term chronic maintenance use of antibiotic treatment in the prior 4 weeks
  4. Oral xanthine derivatives (e.g. theophylline) in the prior 7 days
* A moderate or severe COPD exacerbation or a respiratory tract infection (e.g., pneumonia) that has not resolved ≤14 days prior to the screening visit or during the run-in period
* Current treatment with non-cardioselective β-blockers
* Requirement of long term (\> 15 hours daily) oxygen therapy
* Known respiratory disorders other than COPD which may impact the efficacy of the study drug according to investigator's judgement.
* Lung transplant surgery or lung volume reduction surgery (subjects with lung volume reduction surgery are excluded if the procedure was performed within 1 year before the Screening visit)
* Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator, would prevent use of anticholinergic agents
* History of hypersensitivity to M3 receptor antagonists, β2 agonists, corticosteroids or any of the excipients contained in any of the study drugs used in the trial which may raise contra-indications or impact the efficacy of the study drug according to the investigator's judgement
* Subject has severe, acute or uncontrolled cardiovascular condition (such as but not limited to unstable ischemic heart disease, NYHA Class IV, left ventricular failure, acute myocardial infarction or unstable angina) in the last 6 months
* An abnormal and clinically significant 12-lead ECG at either the screening or randomization visit. This is characterized as but not limited to any of the following findings:

  1. Atrial fibrillation (AF) with rapid ventricular response \> 120 bpm
  2. Ventricular tachycardias (sustained, non-sustained \[\>3 up to 30 sec\])
  3. Evidence of Mobitz Type II second degree or third-degree atrioventricular block
  4. Prolonged QTcF (\>450ms for males, or \>470ms for females). This criterion is not applicable for subjects with a pacemaker or permanent AF.
* Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug according to investigator's judgement
* Unstable or uncontrolled concurrent disease which may impact the efficacy or safety of the study drug or the subject's participation in the study according to investigator's judgment
* Malignancy that has not been in complete remission for at least 1 year or any untreated localized carcinomas
* History of alcohol abuse and/or substance/drug abuse within 12 months prior to the screening visit
* Receipt of any other investigational drug within 1 month or 5 half-lives (whichever is greater) prior to the screening visit or have been previously randomized in this trial, or are currently participating in another clinical trial
* Currently in the acute phase of a pulmonary rehabilitation program within 4 weeks before the screening visit or planning to enroll in the acute phase of such a program during the study. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded
* Mentally or legally incapacitated, or subjects incarcerated as a result of an official or judicial order
* Major surgery in the 3 months prior to the screening visit or have a planned surgery during the trial
* Non-satisfactory compliance with the eDiary (\<65% or \>135%) during the run-in period
* Subjects requiring the use of spacer device or nebulizer for administration of maintenance COPD therapies.
* Veins unsuitable for repeat venipuncture
* Blood donation or blood loss (≥450mL) in the 4 weeks before randomization

Primary outcomes:
measure: Change from baseline in pre-dose morning Forced Expiratory Volume in the 1st second (FEV1) at Week 28
timeFrame: Week 28
Secondary outcomes:
measure: Change from baseline in 2-hour post-dose morning FEV1 at Week 28
timeFrame: Week 28
measure: Rate of moderate and severe COPD exacerbations over 52 weeks of treatment
timeFrame: 52-week treatment period
measure: Change from baseline in pre-dose morning FEV1 at designated clinic visits
timeFrame: Week 4, Week 10, Week 40, & Week 52
measure: Change from baseline in 2-hour post-dose morning FEV1 designated clinic visits
timeFrame: Day 1, Week 4, Week 10, Week 40, & Week 52
measure: Change from pre-dose to 2-hour post-dose morning FEV1 at designated clinic visits
timeFrame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52
measure: FEV1 response (change from baseline in pre-dose morning FEV1 ≥100ml) at designated clinic visits
timeFrame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52
measure: Time to first moderate or severe COPD exacerbation
timeFrame: 52-week treatment period
measure: Rate of severe COPD exacerbations over 52 weeks of treatment
timeFrame: 52-week treatment period
measure: Time to first severe COPD exacerbation
timeFrame: 52-week treatment period
measure: Saint George's Respiratory Questionnaire (SGRQ) response (a decrease from baseline in total score ≥4) at designated clinic visits
timeFrame: Week 4, Week 10, Week 28, Week 40, & Week 52
measure: Change from baseline in the SGRQ total score and domain scores at each designated clinic visit
timeFrame: Week 4, Week 10, Week 28, Week 40, & Week 52
measure: Change from baseline to each inter-visit period in the percentage of days without intake of rescue medication
timeFrame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52
measure: Change from baseline to each inter-visit period in the average use of rescue medication (number of puffs/day)
timeFrame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52
measure: Change from baseline in pre-dose morning Forced Vital Capacity (FVC) at designated clinic visits
timeFrame: Week 4, Week 10, Week 28, Week 40, & Week 52
measure: Change from baseline in 2-hour post-dose morning FVC at designated clinic visits
timeFrame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52
measure: Change from pre-dose to 2-hour post-dose morning FVC at designated clinic visits
timeFrame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52
measure: Change from baseline to each inter-visit period in the average E-RS total score and domain scores
timeFrame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52
measure: Change from baseline in COPD Assessment Test (CAT) score at designated clinic visit
timeFrame: Week 4, Week 10, Week 28, Week 40, & Week 52
measure: CAT response (decrease from baseline ≥2 points) at designated clinic visits
timeFrame: Week 4, Week 10, Week 28, Week 40, & Week 52
measure: Modified Medical Research Council (mMRC) dyspnea scale at designated clinic visits
timeFrame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52
measure: Change from baseline in health-related quality of life (decrease from baseline in total SGRQ score ≥4) over 52 weeks of treatment.
timeFrame: 52-week treatment period
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Chiesi Clinical Trial Site 840350
state: Alabama
city: Dothan
country: United States
facility: Chiesi Clinical Trial Site 840186
state: Alabama
city: Foley
country: United States
facility: Chiesi Clinical Trial Site 840258
state: Alabama
city: Jasper
country: United States
facility: Chiesi Clinical Trial Site 840279
state: Alabama
city: Mobile
country: United States
facility: Chiesi Clinical Trial Site 840433
state: Alabama
city: Montgomery
country: United States
facility: Chiesi Clinical Trial Site 840206
state: Alabama
city: Muscle Shoals
country: United States
facility: Chiesi Clinical Trial Site 840249
state: Alabama
city: Chandler
country: United States
facility: Chiesi Clinical Trial Site 840406
state: Arizona
city: Peoria
country: United States
facility: Chiesi Clinical Trial Site 840402
state: Arizona
city: Tucson
country: United States
facility: Chiesi Clinical Trial Site 840349
state: Arizona
city: Covina
country: United States
facility: Chiesi Clinical Trial Site 840404
state: California
city: Escondido
country: United States
facility: Chiesi Clinical Trial Site 840209
state: California
city: La Palma
country: United States
facility: Chiesi Clinical Trial Site 840427
state: California
city: Lomita
country: United States
facility: Chiesi Clinical Trial Site 840358
state: California
city: Newport Beach
country: United States
facility: Chiesi Clinical Trial Site 840173
state: California
city: Northridge
country: United States
facility: Chiesi Clinical Trial Site 840208
state: California
city: Northridge
country: United States
facility: Chiesi Clinical Trial Site 840277
state: California
city: Redding
country: United States
facility: Chiesi Clinical Trial Site 840364
state: California
city: Sacramento
country: United States
facility: Chiesi Clinical Trial Site 840226
state: California
city: Sacramento
country: United States
facility: Chiesi Clinical Trial Site 840405
state: California
city: San Diego
country: United States
facility: Chiesi Clinical Trial Site 840107
state: California
city: Santa Ana
country: United States
facility: Chiesi Clinical Trial Site 840373
state: California
city: Upland
country: United States
facility: Chiesi Clinical Trial Site 840164
state: California
city: West Covina
country: United States
facility: Chiesi Clinical Trial Site 840174
state: California
city: Westminster
country: United States
facility: Chiesi Clinical Trial Site 840144
state: California
city: Aurora
country: United States
facility: Chiesi Clinical Trial Site 840441
state: Colorado
city: Boulder
country: United States
facility: Chiesi Clinical Trial Site 840229
state: Colorado
city: Norwalk
country: United States
facility: Chiesi Clinical Trial Site 840399
state: Connecticut
city: Altamonte Springs
country: United States
facility: Chiesi Clinical Trial Site 840116
state: Florida
city: Aventura
country: United States
facility: Chiesi Clinical Trial Site 840268
state: Florida
city: Brandon
country: United States
facility: Chiesi Clinical Trial Site 840192
state: Florida
city: Brooksville
country: United States
facility: Chiesi Clinical Trial Site 840310
state: Florida
city: Chiefland
country: United States
facility: Chiesi Clinical Trial Site 840240
state: Florida
city: Clearwater
country: United States
facility: Chiesi Clinical Trial Site 840153
state: Florida
city: Coral Gables
country: United States
facility: Chiesi Clinical Trial Site 840272
state: Florida
city: Coral Gables
country: United States
facility: Chiesi Clinical Trial Site 840304
state: Florida
city: Cutler Bay
country: United States
facility: Chiesi Clinical Trial Site 840193
state: Florida
city: Cutler Bay
country: United States
facility: Chiesi Clinical Trial Site 840311
state: Florida
city: Cutler Bay
country: United States
facility: Chiesi Clinical Trial Site 840335
state: Florida
city: Daytona Beach
country: United States
facility: Chiesi Clinical Trial Site 840141
state: Florida
city: DeLand
country: United States
facility: Chiesi Clinical Trial Site 840133
state: Florida
city: Doral
country: United States
facility: Chiesi Clinical Trial Site 840269
state: Florida
city: Hialeah Gardens
country: United States
facility: Chiesi Clinical Trial Site 840354
state: Florida
city: Hialeah Gardens
country: United States
facility: Chiesi Clinical Trial Site 840256
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840303
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840163
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840165
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840238
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840265
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840241
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840253
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840184
state: Florida
city: Hialeah
country: United States
facility: Chiesi Clinical Trial Site 840267
state: Florida
city: Kissimmee
country: United States
facility: Chiesi Clinical Trial Site 840200
state: Florida
city: Lakeland
country: United States
facility: Chiesi Clinical Trial Site 840232
state: Florida
city: Leesburg
country: United States
facility: Chiesi Clinical Trial Site 840113
state: Florida
city: Miami Beach
country: United States
facility: Chiesi Clinical Trial Site 840319
state: Florida
city: Miami Lakes
country: United States
facility: Chiesi Clinical Trial Site 840328
state: Florida
city: Miami Lakes
country: United States
facility: Chiesi Clinical Trial Site 840378
state: Florida
city: Miami Lakes
country: United States
facility: Chiesi Clinical Trial Site 840288
state: Florida
city: Miami Lakes
country: United States
facility: Chiesi Clinical Trial Site 840385
state: Florida
city: Miami Lakes
country: United States
facility: Chiesi Clinical Trial Site 840353
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840372
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840137
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840289
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840377
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840387
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840326
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840175
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840346
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840347
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840205
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840247
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840341
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840148
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840239
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840312
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840355
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840388
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840237
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840261
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840262
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840280
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840178
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840292
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840202
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840275
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840122
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840352
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840235
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840360
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840381
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840243
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840244
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840257
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840380
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840382
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840367
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840162
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840166
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840370
state: Florida
city: Miami
country: United States
facility: Chiesi Clinical Trial Site 840392
state: Florida
city: Mount Dora
country: United States
facility: Chiesi Clinical Trial Site 840140
state: Florida
city: New Port Richey
country: United States
facility: Chiesi Clinical Trial Site 840263
state: Florida
city: North Miami Beach
country: United States
facility: Chiesi Clinical Trial Site 840161
state: Florida
city: North Miami
country: United States
facility: Chiesi Clinical Trial Site 840132
state: Florida
city: Orlando
country: United States
facility: Chiesi Clinical Trial Site 840255
state: Florida
city: Orlando
country: United States
facility: Chiesi Clinical Trial Site 840110
state: Florida
city: Orlando
country: United States
facility: Chiesi Clinical Trial Site 840125
state: Florida
city: Palmetto Bay
country: United States
facility: Chiesi Clinical Trial Site 840121
state: Florida
city: Pembroke Pines
country: United States
facility: Chiesi Clinical Trial Site 840196
state: Florida
city: Pembroke Pines
country: United States
facility: Chiesi Clinical Trial Site 840198
state: Florida
city: Plantation
country: United States
facility: Chiesi Clinical Trial Site 840363
state: Florida
city: Plantation
country: United States
facility: Chiesi Clinical Trial Site 840371
state: Florida
city: Pompano Beach
country: United States
facility: Chiesi Clinical Trial Site 840252
state: Florida
city: Port Charlotte
country: United States
facility: Chiesi Clinical Trial Site 840105
state: Florida
city: Saint Petersburg
country: United States
facility: Chiesi Clinical Trial Site 840291
state: Florida
city: Sarasota
country: United States
facility: Chiesi Clinical Trial Site 840294
state: Florida
city: Tampa
country: United States
facility: Chiesi Clinical Trial Site 840313
state: Florida
city: Tampa
country: United States
facility: Chiesi Clinical Trial Site 840356
state: Florida
city: Tampa
country: United States
facility: Chiesi Clinical Trial Site 840379
state: Florida
city: Tampa
country: United States
facility: Chiesi Clinical Trial Site 840131
state: Florida
city: Tampa
country: United States
facility: Chiesi Clinical Trial Site 840324
state: Florida
city: Tampa
country: United States
facility: Chiesi Clinical Trial Site 840309
state: Florida
city: The Villages
country: United States
facility: Chiesi Clinical Trial Site 840210
state: Florida
city: Winter Park
country: United States
facility: Chiesi Clinical Trial Site 840129
state: Florida
city: Adairsville
country: United States
facility: Chiesi Clinical Trial Site 840223
state: Georgia
city: Columbus
country: United States
facility: Chiesi Clinical Trial Site 840218
state: Georgia
city: Columbus
country: United States
facility: Chiesi Clinical Trial Site 840414
state: Georgia
city: Cordele
country: United States
facility: Chiesi Clinical Trial Site 840437
state: Georgia
city: Lawrenceville
country: United States
facility: Chiesi Clinical Trial Site 840390
state: Georgia
city: Lawrenceville
country: United States
facility: Chiesi Clinical Trial Site 840227
state: Georgia
city: Rincon
country: United States
facility: Chiesi Clinical Trial Site 840138
state: Georgia
city: Stonecrest
country: United States
facility: Chiesi Clinical Trial Site 840417
state: Georgia
city: Union City
country: United States
facility: Chiesi Clinical Trial Site 840383
state: Georgia
city: Chicago Ridge
country: United States
facility: Chiesi Clinical Trial Site 840365
state: Illinois
city: Chicago
country: United States
facility: Chiesi Clinical Trial Site 840321
state: Illinois
city: Hammond
country: United States
facility: Chiesi Clinical Trial Site 840407
state: Indiana
city: Valparaiso
country: United States
facility: Chiesi Clinical Trial Site 840108
state: Indiana
city: Council Bluffs
country: United States
facility: Chiesi Clinical Trial Site 840318
state: Iowa
city: Crowley
country: United States
facility: Chiesi Clinical Trial Site 840207
state: Louisiana
city: Zachary
country: United States
facility: Chiesi Clinical Trial Site 840436
state: Louisiana
city: Bangor
country: United States
facility: Chiesi Clinical Trial Site 840451
state: Maine
city: Baltimore
country: United States
facility: Chiesi Clinical Trial Site 840447
state: Maryland
city: Baltimore
country: United States
facility: Chiesi Clinical Trial Site 840376
state: Maryland
city: Westminster
country: United States
facility: Chiesi Clinical Trial Site 840199
state: Maryland
city: Fall River
country: United States
facility: Chiesi Clinical Trial Site 840214
state: Massachusetts
city: New Bedford
country: United States
facility: Chiesi Clinical Trial Site 840322
state: Massachusetts
city: North Dartmouth
country: United States
facility: Chiesi Clinical Trial site 840250
state: Massachusetts
city: Dearborn
country: United States
facility: Chiesi Clinical Trial Site 840325
state: Michigan
city: Dearborn
country: United States
facility: Chiesi Clinical Trial Site 840400
state: Michigan
city: Farmington Hills
country: United States
facility: Chiesi Clinical Trial Site 840183
state: Michigan
city: Flint
country: United States
facility: Chiesi Clinical Trial Site 840340
state: Michigan
city: Flint
country: United States
facility: Chiesi Clinical Trial Site 840401
state: Michigan
city: Novi
country: United States
facility: Chiesi Clinical Trial Site 840345
state: Michigan
city: Southfield
country: United States
facility: Chiesi Clinical Trial Site 840287
state: Michigan
city: Southfield
country: United States
facility: Chiesi Clinical Trial Site 840415
state: Michigan
city: Fayette
country: United States
facility: Chiesi Clinical Trial Site 840444
state: Mississippi
city: Ridgeland
country: United States
facility: Chiesi Clinical Trial Site 840448
state: Mississippi
city: Chesterfield
country: United States
facility: Chiesi Clinical Trial Site 840278
state: Missouri
city: Columbia
country: United States
facility: Chiesi Clinical Trial Site 840155
state: Missouri
city: Richmond Heights
country: United States
facility: Chiesi Clinical Trial Site 840316
state: Missouri
city: Saint Charles
country: United States
facility: Chiesi Clinical Trial Site 840150
state: Missouri
city: Saint Louis
country: United States
facility: Chiesi Clinical Trial Site 840282
state: Missouri
city: Saint Louis
country: United States
facility: Chiesi Clinical Trial Site 840123
state: Missouri
city: Saint Louis
country: United States
facility: Chiesi Clinical Trial Site 840142
state: Missouri
city: Missoula
country: United States
facility: Chiesi Clinical Trial Site 840273
state: Montana
city: Lincoln
country: United States
facility: Chiesi Clinical Trial Site 840281
state: Nebraska
city: Omaha
country: United States
facility: Chiesi Clinical Trial Site 840329
state: Nebraska
city: Las Vegas
country: United States
facility: Chiesi Clinical Trial Site 840213
state: Nevada
city: Las Vegas
country: United States
facility: Chiesi Clinical Trial Site 840285
state: Nevada
city: Las Vegas
country: United States
facility: Chiesi Clinical Trial Site 840299
state: Nevada
city: Portsmouth
country: United States
facility: Chiesi Clinical Trial Site 840338
state: New Hampshire
city: Berlin
country: United States
facility: Chiesi Clinical Trial Site 840297
state: New Jersey
city: Toms River
country: United States
facility: Chiesi Clinical Trial Site 840333
state: New Jersey
city: Binghamton
country: United States
facility: Chiesi Clinical Trial Site 840330
state: New York
city: Bronx
country: United States
facility: Chiesi Clinical Trial Site 840128
state: New York
city: Brooklyn
country: United States
facility: Chiesi Clinical Trial Site 840397
state: New York
city: Buffalo
country: United States
facility: Chiesi Clinical Trial Site 840254
state: New York
city: Buffalo
country: United States
facility: Chiesi Clinical Trial Site 840307
state: New York
city: Flushing
country: United States
facility: Chiesi Clinical Trial Site 840368
state: New York
city: New Windsor
country: United States
facility: Chiesi Clinical Trial Site 840362
state: New York
city: Charlotte
country: United States
facility: Chiesi Clinical Trial Site 840215
state: North Carolina
city: Charlotte
country: United States
facility: Chiesi Clinical Trial Site 840366
state: North Carolina
city: Charlotte
country: United States
facility: Chiesi Clinical Trial Site 840158
state: North Carolina
city: Denver
country: United States
facility: Chiesi Clinical Trial Site 840409
state: North Carolina
city: Durham
country: United States
facility: Chiesi Clinical Trial Site 840403
state: North Carolina
city: Gastonia
country: United States
facility: Chiesi Clinical Trial Site 840428
state: North Carolina
city: Huntersville
country: United States
facility: Chiesi Clinical Trial Site 840236
state: North Carolina
city: Monroe
country: United States
facility: Chiesi Clinical Trial Site 840259
state: North Carolina
city: Morgantown
country: United States
facility: Chiesi Clinical Trial Site 840440
state: North Carolina
city: New Bern
country: United States
facility: Chiesi Clinical Trial Site 840194
state: North Carolina
city: Raleigh
country: United States
facility: Chiesi Clinical Trial Site 840120
state: North Carolina
city: Raleigh
country: United States
facility: Chiesi Clinical Trial Site 840438
state: North Carolina
city: Raleigh
country: United States
facility: Chiesi Clinical Trial Site 840429
state: North Carolina
city: Rocky Mount
country: United States
facility: Chiesi Clinical Trial Site 840112
state: North Carolina
city: Shelby
country: United States
facility: Chiesi Clinical Trial Site 840135
state: North Carolina
city: Wilmington
country: United States
facility: Chiesi Clinical Trial Site 840189
state: North Carolina
city: Winston-Salem
country: United States
facility: Chiesi Clinical Trial Site 840412
state: North Carolina
city: Akron
country: United States
facility: Chiesi Clinical Trial Site 840445
state: Ohio
city: Cincinnati
country: United States
facility: Chiesi Clinical Trial Site 840104
state: Ohio
city: Cincinnati
country: United States
facility: Chiesi Clinical Trial Site 840357
state: Ohio
city: Columbus
country: United States
facility: Chiesi Clinical Trial Site 840124
state: Ohio
city: Dayton
country: United States
facility: Chiesi Clinical Trial Site 840426
state: Ohio
city: Kettering
country: United States
facility: Chiesi Clinical Trial Site 840302
state: Ohio
city: Maumee
country: United States
facility: Chiesi Clinical Trial Site 840233
state: Ohio
city: Middleburg Heights
country: United States
facility: Chiesi Clinical Trial Site 840167
state: Ohio
city: Toledo
country: United States
facility: Chiesi Clinical Trial Site 840157
state: Ohio
city: Medford
country: United States
facility: Chiesi Clinical Trial Site 840203
state: Oregon
city: Beaver
country: United States
facility: Chiesi Clinical Trial Site 840300
state: Pennsylvania
city: DuBois
country: United States
facility: Chiesi Clinical Trial Site 840308
state: Pennsylvania
city: Jenkintown
country: United States
facility: Chiesi Clinical Trial Site 840156
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Chiesi Clinical Trial Site 840327
state: Pennsylvania
city: Scotland
country: United States
facility: Chiesi Clinical Trial Site 840418
state: Pennsylvania
city: Smithfield
country: United States
facility: Chiesi Clinical Trial Site 840419
state: Pennsylvania
city: Cranston
country: United States
facility: Chiesi Clinical Trial Site 840450
state: Rhode Island
city: Cumberland
country: United States
facility: Chiesi Clinical Trial Site 840332
state: Rhode Island
city: Anderson
country: United States
facility: Chiesi Clinical Trial Site 840222
state: South Carolina
city: Anderson
country: United States
facility: Chiesi Clinical Trial Site 840435
state: South Carolina
city: Charleston
country: United States
facility: Chiesi Clinical Trial Site 840431
state: South Carolina
city: Columbia
country: United States
facility: Chiesi Clinical Trial Site 840334
state: South Carolina
city: Columbia
country: United States
facility: Chiesi Clinical Trial Site 840130
state: South Carolina
city: Columbia
country: United States
facility: Chiesi Clinical Trial Site 840430
state: South Carolina
city: Fort Mill
country: United States
facility: Chiesi Clinical Trial Site 840211
state: South Carolina
city: Gaffney
country: United States
facility: Chiesi Clinical Trial Site 840182
state: South Carolina
city: Greenville
country: United States
facility: Chiesi Clinical Trial Site 840111
state: South Carolina
city: Lancaster
country: United States
facility: Chiesi Clinical Trial Site 840420
state: South Carolina
city: Mauldin
country: United States
facility: Chiesi Clinical Trial Site 840386
state: South Carolina
city: Rock Hill
country: United States
facility: Chiesi Clinical Trial Site 840100
state: South Carolina
city: Spartanburg
country: United States
facility: Chiesi Clinical Trial Site 840375
state: South Carolina
city: Union
country: United States
facility: Chiesi Clinical Trial Site 840106
state: South Carolina
city: West Columbia
country: United States
facility: Chiesi Clinical Trial Site 840295
state: South Carolina
city: Rapid City
country: United States
facility: Chiesi Clinical Trial Site 840398
state: South Dakota
city: Chattanooga
country: United States
facility: Chiesi Clinical Trial Site 840305
state: Tennessee
city: Franklin
country: United States
facility: Chiesi Clinical Trial Site 840351
state: Tennessee
city: Johnson City
country: United States
facility: Chiesi Clinical Trial Site 840306
state: Tennessee
city: Knoxville
country: United States
facility: Chiesi Clinical Trial Site 840171
state: Tennessee
city: Nashville
country: United States
facility: Chiesi Clinical Trial Site 840361
state: Tennessee
city: Tullahoma
country: United States
facility: Chiesi Clinical Trial Site 840271
state: Tennessee
city: Baytown
country: United States
facility: Chiesi Clinical Trial Site 840101
state: Texas
city: Boerne
country: United States
facility: Chiesi Clinical Trial Site 840114
state: Texas
city: Cypress
country: United States
facility: Chiesi Clinical Trial Site 840146
state: Texas
city: Dallas
country: United States
facility: Chiesi Clinical Trial Site 840413
state: Texas
city: Houston
country: United States
facility: Chiesi Clinical Trial Site 840284
state: Texas
city: Houston
country: United States
facility: Chiesi Clinical Trial Site 840411
state: Texas
city: Houston
country: United States
facility: Chiesi Clinical Trial Site 840389
state: Texas
city: Houston
country: United States
facility: Chiesi Clinical Trial Site 840185
state: Texas
city: Houston
country: United States
facility: Chiesi Clinical Trial Site 840224
state: Texas
city: Humble
country: United States
facility: Chiesi Clinical Trial Site 840408
state: Texas
city: Katy
country: United States
facility: Chiesi Clinical Trial Site 840102
state: Texas
city: Katy
country: United States
facility: Chiesi Clinical Trial Site 840274
state: Texas
city: Kerrville
country: United States
facility: Chiesi Clinical Trial Site 840432
state: Texas
city: Lampasas
country: United States
facility: Chiesi Clinical Trial Site 840160
state: Texas
city: McAllen
country: United States
facility: Chiesi Clinical Trial Site 840424
state: Texas
city: McKinney
country: United States
facility: Chiesi Clinical Trial Site 840119
state: Texas
city: Nederland
country: United States
facility: Chiesi Clinical Trial Site 840442
state: Texas
city: North Richland Hills
country: United States
facility: Chiesi Clinical Trial Site 840176
state: Texas
city: Pearland
country: United States
facility: Chiesi Clinical Trial Site 840283
state: Texas
city: San Antonio
country: United States
facility: Chiesi Clinical Trial Site 840191
state: Texas
city: San Antonio
country: United States
facility: Chiesi Clinical Trial Site 840320
state: Texas
city: San Antonio
country: United States
facility: Chiesi Clinical Trial Site 840410
state: Texas
city: Sherman
country: United States
facility: Chiesi Clinical Trial Site 840231
state: Texas
city: Sherman
country: United States
facility: Chiesi Clinical Trial Site 840396
state: Texas
city: Splendora
country: United States
facility: Chiesi Clinical Trial Site 840394
state: Texas
city: Sugar Land
country: United States
facility: Chiesi Clinical Trial Site 840221
state: Texas
city: Tomball
country: United States
facility: Chiesi Clinical Trial Site 840139
state: Texas
city: Tomball
country: United States
facility: Chiesi Clinical Trial Site 840314
state: Texas
city: Colchester
country: United States
facility: Chiesi Clinical Trial Site 840337
state: Vermont
city: Manassas
country: United States
facility: Chiesi Clinical Trial Site 840264
state: Virginia
city: Richmond
country: United States
facility: Chiesi Clinical Trial Site 840159
state: Virginia
city: Richmond
country: United States
facility: Chiesi Clinical Trial Site 840425
state: Virginia
city: Everett
country: United States
facility: Chiesi Clinical Trial Site 840423
state: Washington
city: Renton
country: United States
facility: Chiesi Clinical Trial Site 840342
state: Washington
city: Vancouver
country: United States
facility: Chiesi Clinical Trial Site 840154
state: Washington
city: Kingwood
country: United States
facility: Chiesi Clinical Trial Site 840421
state: West Virginia
city: Morgantown
country: United States
facility: Chiesi Clinical Trial Site 840201
state: West Virginia
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Chiesi Clinical Trial Site 032115
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Chiesi Clinical Trial Site 032113
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Chiesi Clinical Trial Site 032107
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Chiesi Clinical Trial Site 032112
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Chiesi Clinical Trial Site 032121
state: Buenos Aires
city: Florencio Varela
country: Argentina
facility: Chiesi Clinical Trial Site 032110
state: Buenos Aires
city: La Plata
country: Argentina
facility: Chiesi Clinical Trial Site 032108
state: Buenos Aires
city: Mar Del Plata
country: Argentina
facility: Chiesi Clinical Trial Site 032118
state: Buenos Aires
city: Mar Del Plata
country: Argentina
facility: Chiesi Clinical Trial Site 032114
state: Buenos Aires
city: Monte Grande
country: Argentina
facility: Chiesi Clinical Trial Site 032102
state: Buenos Aires
city: Quilmes
country: Argentina
facility: Chiesi Clinical Trial Site 032106
state: Buenos Aires
city: San Fernando
country: Argentina
facility: Chiesi Clinical Trial Site 032116
state: Buenos Aires
city: Vicente López
country: Argentina
facility: Chiesi Clinical Trial Site 032100
state: Buenos Aires
city: Córdoba
country: Argentina
facility: Chiesi Clinical Trial Site 032111
state: Cordoba
city: Concepción Del Uruguay
country: Argentina
facility: Chiesi Clinical Trial Site 032120
state: Entre Rios
city: Rosario
country: Argentina
facility: Chiesi Clinical Trial Site 032101
state: Santa Fe
city: Rosario
country: Argentina
facility: Chiesi Clinical Trial Site 032132
state: Santa Fe
city: Tucumán
country: Argentina
facility: Chiesi Clinical Trial Site 032117
state: Tucuman
city: Buenos Aires
country: Argentina
facility: Chiesi Clinical Trial Site 032125
city: Buenos Aires
country: Argentina
facility: Chiesi Clinical Trial Site 032130
city: Buenos Aires
country: Argentina
facility: Chiesi Clinical Trial Site 032133
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Chiesi Clinical Trial Site 032103
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Chiesi Clinical Trial Site 032109
city: Córdoba
country: Argentina
facility: Chiesi Clinical Trial Site 032122
city: Lobos
country: Argentina
facility: Chiesi Clinical Trial Site 032131
city: Mar Del Plata
country: Argentina
facility: Chiesi Clinical Trial Site 032119
city: Mendoza
country: Argentina
facility: Chiesi Clinical Trial Site 032105
city: Mendoza
country: Argentina
facility: Chiesi Clinical Trial Site 032129
city: Mendoza
country: Argentina
facility: Chiesi Clinical Trial Site 032126
city: Paraná
country: Argentina
facility: Chiesi Clinical Trial Site 032123
city: Rosario
country: Argentina
facility: Chiesi Clinical Trial Site 032128
city: San Miguel De Tucumán
country: Argentina
facility: Chiesi Clinical Trial Site 032134
city: San Miguel De Tucumán
country: Argentina
facility: Chiesi Clinical Trial Site 032136
city: San Rafael
country: Argentina
facility: Chiesi Clinical Trial Site 032127
city: Santa Fe
country: Argentina
facility: Chiesi Clinical Trial Site 032124
city: Gabrovo
country: Bulgaria
facility: Chiesi Clinical Trial Site 100125
city: Haskovo
country: Bulgaria
facility: Chiesi Clinical Trial Site 100109
city: Kozloduy
country: Bulgaria
facility: Chiesi Clinical Trial Site 100129
city: Lovech
country: Bulgaria
facility: Chiesi Clinical Trial Site 100111
city: Montana
country: Bulgaria
facility: Chiesi Clinical Trial Site 100115
city: Pleven
country: Bulgaria
facility: Chiesi Clinical Trial Site 100132
city: Pleven
country: Bulgaria
facility: Chiesi Clinical Trial Site 100101
city: Plovdiv
country: Bulgaria
facility: Chiesi Clinical Trial Site 100131
city: Plovdiv
country: Bulgaria
facility: Chiesi Clinical Trial Site 100102
city: Plovdiv
country: Bulgaria
facility: Chiesi Clinical Trial Site 100126
city: Razgrad
country: Bulgaria
facility: Chiesi Clinical Trial Site 100128
city: Ruse
country: Bulgaria
facility: Chiesi Clinical Trial Site 100104
city: Ruse
country: Bulgaria
facility: Chiesi Clinical Trial Site 100113
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100100
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100110
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100112
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100116
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100117
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100118
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100119
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100121
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100123
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100124
city: Sofia
country: Bulgaria
facility: Chiesi Clinical Trial Site 100127
city: Stara Zagora
country: Bulgaria
facility: Chiesi Clinical Trial Site 100103
city: Stara Zagora
country: Bulgaria
facility: Chiesi Clinical Trial Site 100107
city: Varna
country: Bulgaria
facility: Chiesi Clinical Trial Site 100130
city: Veliko Tarnovo
country: Bulgaria
facility: Chiesi Clinical Trial Site 100122
city: Vidin
country: Bulgaria
facility: Chiesi Clinical Trial Site 100106
city: Vidin
country: Bulgaria
facility: Chiesi Clinical Trial Site 100114
city: Edmonton
country: Canada
facility: Chiesi Clinical Trial Site 124103
state: Alberta
city: Sherwood Park
country: Canada
facility: Chiesi Clinical Trial Site 124105
state: Alberta
city: Burlington
country: Canada
facility: Chiesi Clinical Trial Site 124102
state: Ontario
city: Sudbury
country: Canada
facility: Chiesi Clinical Trial Site 124104
state: Ontario
city: Windsor
country: Canada
facility: Chiesi Clinical Trial Site 124100
state: Ontario
city: Trois-Rivières
country: Canada
facility: Chiesi Clinical Trial Site 124106
state: Quebec
city: Brandýs Nad Labem
country: Czechia
facility: Chiesi Clinical Trial Site 203101
city: Jindřichův Hradec
country: Czechia
facility: Chiesi Clinical Trial Site 203107
city: Miroslav
country: Czechia
facility: Chiesi Clinical Trial Site 203109
city: Praha
country: Czechia
facility: Chiesi Clinical Trial Site 203116
city: Praha
country: Czechia
facility: Chiesi Clinical Trial Site 203115
city: Praha
country: Czechia
facility: Chiesi Clinical Trial Site 203114
city: Rokycany
country: Czechia
facility: Chiesi Clinical Trial Site 203112
city: Strakonice
country: Czechia
facility: Chiesi Clinical Trial Site 203108
city: Teplice
country: Czechia
facility: Chiesi Clinical Trial Site 203104
city: Tábor
country: Czechia
facility: Chiesi Clinical Trial Site 203105
city: Varnsdorf
country: Czechia
facility: Chiesi Clinical Trial Site 203110
city: Komló
country: Hungary
facility: Chiesi Clinical Trial Site 348121
state: BA
city: Pécs
country: Hungary
facility: Chiesi Clinical Trial Site 348122
state: BA
city: Csorna
country: Hungary
facility: Chiesi Clinical Trial Site 348124
state: GS
city: Szolnok
country: Hungary
facility: Chiesi Clinical Trial Site 348126
state: JN
city: Balassagyarmat
country: Hungary
facility: Chiesi Clinical Trial Site 348107
state: Nograd
city: Gödöllő
country: Hungary
facility: Chiesi Clinical Trial Site 348120
state: Pest
city: Nyiregyhaza
country: Hungary
facility: Chiesi Clinical Trial Site 348104
state: Szabolcs-Szatmar-Bereg
city: Nyiregyhaza
country: Hungary
facility: Chiesi Clinical Trial Site 348109
state: Szabolcs-Szatmár-Bereg
city: Szombathely
country: Hungary
facility: Chiesi Clinical Trial Site 348105
state: Vas
city: Debrecen
country: Hungary
facility: Chiesi Clinical Trial Site 348118
city: Hajdúnánás
country: Hungary
facility: Chiesi Clinical Trial Site 348112
city: Hatvan
country: Hungary
facility: Chiesi Clinical Trial Site 348116
city: Monor
country: Hungary
facility: Chiesi Clinical Trial Site 348103
city: Sellye
country: Hungary
facility: Chiesi Clinical Trial Site 348125
city: Tijuana
country: Mexico
facility: Chiesi Clinical Trial Site 484110
state: Baja California
city: Cuauhtémoc
country: Mexico
facility: Chiesi Clinical Trial Site 484103
state: Cdmx
city: Guadalajara
country: Mexico
facility: Chiesi Clinical Trial Site 484113
state: Jalisco
city: Guadalajara
country: Mexico
facility: Chiesi Clinical Trial Site 484100
state: Jalisco
city: Guadalajara
country: Mexico
facility: Chiesi Clinical Trial Site 484102
state: Jalisco
city: Guadalajara
country: Mexico
facility: Chiesi Clinical Trial Site 484104
state: Jalisco
city: Guadalajara
country: Mexico
facility: Chiesi Clinical Trial Site 484106
state: Jalisco
city: Guadalajara
country: Mexico
facility: Chiesi Clinical Trial Site 484112
state: Jalisco
city: Guadalupe
country: Mexico
facility: Chiesi Clinical Trial Site 484115
state: Jalisco
city: Morelia
country: Mexico
facility: Chiesi Clinical Trial Site 484107
state: Michoacan
city: Monterrey
country: Mexico
facility: Chiesi Clinical Trial Site 484101
state: Nuevo Leon
city: Monterrey
country: Mexico
facility: Chiesi Clinical Trial Site 484111
state: Nuevo Leon
city: Chihuahua
country: Mexico
facility: Chiesi Clinical Trial Site 484116
city: Chihuahua
country: Mexico
facility: Chiesi Clinical Trial Site 484105
city: Chihuahua
country: Mexico
facility: Chiesi Clinical Trial Site 484109
city: Tlalpan
country: Mexico
facility: Chiesi Clinical Trial Site 484108
city: Białystok
country: Poland
facility: Chiesi Clinical Trial Site 616125
city: Białystok
country: Poland
facility: Chiesi Clinical Trial Site 616119
city: Gizycko
country: Poland
facility: Chiesi Clinical Trial Site 616100
city: Grudziądz
country: Poland
facility: Chiesi Clinical Trial Site 616113
city: Katowice
country: Poland
facility: Chiesi Clinical Trial Site 616116
city: Kraków
country: Poland
facility: Chiesi Clinical Trial Site 616122
city: Kraków
country: Poland
facility: Chiesi Clinical Trial Site 616106
city: Kraków
country: Poland
facility: Chiesi Clinical Trial Site 616109
city: Kraków
country: Poland
facility: Chiesi Clinical Trial Site 616118
city: Olsztyn
country: Poland
facility: Chiesi Clinical Trial Site 616128
city: Ostrowiec
country: Poland
facility: Chiesi Clinical Trial Site 616117
city: Ostróda
country: Poland
facility: Chiesi Clinical Trial Site 616105
city: Poznań
country: Poland
facility: Chiesi Clinical Trial Site 616123
city: Poznań
country: Poland
facility: Chiesi Clinical Trial Site 616107
city: Poznań
country: Poland
facility: Chiesi Clinical Trial Site 616110
city: Rzeszów
country: Poland
facility: Chiesi Clinical Trial Site 616108
city: Skierniewice
country: Poland
facility: Chiesi Clinical Trial Site 616114
city: Skorzewo
country: Poland
facility: Chiesi Clinical Trial Site 616120
city: Sosnowiec
country: Poland
facility: Chiesi Clinical Trial Site 616102
city: Tarnów
country: Poland
facility: Chiesi Clinical Trial Site 616111
city: Toruń
country: Poland
facility: Chiesi Clinical Trial Site 616115
city: Warszawa
country: Poland
facility: Chiesi Clinical Trial Site 616127
city: Wrocław
country: Poland
facility: Chiesi Clinical Trial Site 616126
city: Wrocław
country: Poland
facility: Chiesi Clinical Trial Site 616104
city: Wrocław
country: Poland
facility: Chiesi Clinical Trial Site 616112
city: Zawadzkie
country: Poland
facility: Chiesi Clinical Trial Site 616101
city: Łódź
country: Poland
facility: Chiesi Clinical Trial Site 616103
city: Guaynabo
country: Puerto Rico
facility: Chiesi Clinical Trial Site 840393
city: Oradea
country: Romania
facility: Chiesi Clinical Trial Site 642102
state: Bihor
city: Cluj-Napoca
country: Romania
facility: Chiesi Clinical Trial Site 642104
state: Cluj
city: Deva
country: Romania
facility: Chiesi Clinical Trial Site 642120
state: Hunedoara
city: Bragadiru
country: Romania
facility: Chiesi Clinical Trial Site 642107
state: Ilfov
city: Timişoara
country: Romania
facility: Chiesi Clinical Trial Site 642119
state: Timis
city: Bacău
country: Romania
facility: Chiesi Clinical Trial Site 642109
city: Bragadiru
country: Romania
facility: Chiesi Clinical Trial Site 642106
city: Braşov
country: Romania
facility: Chiesi Clinical Trial Site 642117
city: Bucharest
country: Romania
facility: Chiesi Clinical Trial Site 642103
city: Bucharest
country: Romania
facility: Chiesi Clinical Trial Site 642113
city: Bucuresti
country: Romania
facility: Chiesi Clinical Trial Site 642108
city: Caracal
country: Romania
facility: Chiesi Clinical Trial Site 642115
city: Cluj-Napoca
country: Romania
facility: Chiesi Clinical Trial Site 642111
city: Constanţa
country: Romania
facility: Chiesi Clinical Trial Site 642105
city: Craiova
country: Romania
facility: Chiesi Clinical Trial Site 642110
city: Craiova
country: Romania
facility: Chiesi Clinical Trial Site 642118
city: Iaşi
country: Romania
facility: Chiesi Clinical Trial Site 642101
city: Reșca
country: Romania
facility: Chiesi Clinical Trial Site 642114
city: Satu Mare
country: Romania
facility: Chiesi Clinical Trial Site 642112
city: Timişoara
country: Romania
facility: Chiesi Clinical Trial Site 642116
Study officials:
affiliation: Vitalink Research - Spartanburg
name: Gregory M Feldman, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27.
citation: Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006 Feb;27(2):397-412. doi: 10.1183/09031936.06.00025805. No abstract available.
citation: Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0.
citation: Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. doi: 10.1371/journal.pmed.0030442.
citation: Montes de Oca M, Perez-Padilla R, Talamo C, Halbert RJ, Moreno D, Lopez MV, Muino A, Jose Roberto BJ, Valdivia G, Pertuze J, Ana Maria BM; PLATINO Team. Acute bronchodilator responsiveness in subjects with and without airflow obstruction in five Latin American cities: the PLATINO study. Pulm Pharmacol Ther. 2010 Feb;23(1):29-35. doi: 10.1016/j.pupt.2009.09.005. Epub 2009 Oct 8.
citation: Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999 Jul;54(7):581-6. doi: 10.1136/thx.54.7.581.
citation: Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509.
citation: Lane DC, Stemkowski S, Stanford RH, Tao Z. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study. J Manag Care Spec Pharm. 2018 Nov;24(11):1165-1172. doi: 10.18553/jmcp.2018.24.11.1165.
citation: Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.
citation: Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Oct 15;180(8):741-50. doi: 10.1164/rccm.200904-0492OC. Epub 2009 Jul 30.
citation: Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002. Epub 2011 Oct 29.
citation: Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD; Korean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study group. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012 Mar;106(3):382-9. doi: 10.1016/j.rmed.2011.09.004. Epub 2011 Oct 4.
citation: Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.
citation: Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16.
citation: Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1.
citation: Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017 May 13;389(10082):1919-1929. doi: 10.1016/S0140-6736(17)30188-5. Epub 2017 Apr 3.
citation: Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9.
citation: Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, Agusti A; FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014 Aug;108(8):1153-62. doi: 10.1016/j.rmed.2014.05.013. Epub 2014 Jun 6.
citation: Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med. 2011 Aug 11;11:42. doi: 10.1186/1471-2466-11-42.
citation: Mullerova H, Dransfield MT, Thomashow B, Jones PW, Rennard S, Karlsson N, Fageras M, Metzdorf N, Petruzzelli S, Rommes J, Sciurba FC, Tabberer M, Merrill D, Tal-Singer R. Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test. Am J Respir Crit Care Med. 2020 May 1;201(9):1058-1067. doi: 10.1164/rccm.201907-1369PP. No abstract available.
citation: Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man WD. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014 Mar;2(3):195-203. doi: 10.1016/S2213-2600(14)70001-3. Epub 2014 Feb 4.
citation: Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available.
citation: Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten C, Gustafsson P, Jensen R, Macintyre N, McKay RT, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of lung function testing: the authors' replies to readers' comments. Eur Respir J. 2010 Dec;36(6):1496-8. doi: 10.1183/09031936.00130010. No abstract available.
citation: Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196-204. doi: 10.7326/0003-4819-106-2-196.
citation: Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22. doi: 10.1164/ajrccm.157.5.9709032.
citation: Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005 Mar;2(1):75-9. doi: 10.1081/copd-200050513.
citation: Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med. 2005 Dec;99 Suppl B:S11-8. doi: 10.1016/j.rmed.2005.09.011. Epub 2005 Oct 19.
citation: Jones PW, Gelhorn H, Wilson H, Karlsson N, Menjoge S, Mullerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M. Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire. Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131. doi: 10.15326/jcopdf.4.2.2017.0130.
citation: Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004 Jul;126(1):213-9. doi: 10.1378/chest.126.1.213.
citation: Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis. 2001 Jul;7(4):211-6.
citation: Roger JH, Bratton DJ, Mayer B, Abellan JJ, Keene ON. Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment. Pharm Stat. 2019 Jan;18(1):85-95. doi: 10.1002/pst.1910. Epub 2018 Nov 8.
citation: Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002 Mar;35(3):716-21. doi: 10.1053/jhep.2002.31250.
citation: Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011 Apr;33(7):739-47. doi: 10.1111/j.1365-2036.2011.04590.x. Epub 2011 Feb 9.